Compare Neurocrine Biosciences Inc (NBIX) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs T-Mobile Us Inc — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while T-Mobile Us Inc trades at $148.58 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 12.8× Neurocrine Biosciences Inc's market cap, and T-Mobile Us Inc pays a 2.73% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and T-Mobile Us Inc for 84 Days on average.
| NBIX | TMUS | |
|---|---|---|
Market Cap | $14.36B | $183.76B |
Volume | 1,237,180 | 4,294,650 |
Sector | Health | Media |
52-Week High | $185.50 | $230.06 |
52-Week Low | $123.10 | $161.73 |
Typical Hold Time | 23 Days | 84 Days |
Enterprise Value | $14.37B | $300.37B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
TMUS trades at $171.31, up 2.2% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth to $88.31B in 2025. The company announced a 15% dividend hike and is advancing AI-driven 5G network upgrades, while maintaining robust profitability with a net margin of 11.45%.
Outlook remains positive given earnings momentum and strategic initiatives, but risks include high debt levels and competitive pressures. The consensus price target of $231.10 implies significant upside, supported by 79.6% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
